Pancreas
Daraxonrasib doubles survival in advanced pancreatic cancer trial

  • August 26

Colon
Noninvasive neuromodulation reduces fecal incontinence in phase 3 trial

  • August 26

Esophagus
AGA update sets limits on endoscopic surveillance in older adults

  • August 24

Liver
Vietnamese American patients faced highest liver cancer risk, study finds

  • August 25

Pancreas

FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

  • August 26

Daraxonrasib, marketed as Rasonque, roughly doubled median overall survival compared with chemotherapy in previously treated patients in the phase 3 RASolute 302 trial.

BROWSE BY TOPICS

The New Gastroenterologist

Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist

  • August 3

  • by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR

GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.

Esophagus
Bridging the rural divide: Building a motility center in a critical access hospital

  • August 3

  • by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF

“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”

Is professional coaching worth it? A practical guide for early-career gastroenterologists

  • August 3

  • by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG

Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.

The Latest

August 26
Colon
Noninvasive neuromodulation reduces fecal incontinence in phase 3 trial

  • by Doug Brunk

Six weeks of translumbosacral magnetic stimulation cut fecal incontinence episodes by at least half in up to 81% of patients and improved measures of nerve and sphincter function.

August 26
Pancreas
FDA approves first RAS-targeted therapy for metastatic pancreatic cancer

  • by Bob Alaburda

Daraxonrasib, marketed as Rasonque, roughly doubled median overall survival compared with chemotherapy in previously treated patients in the phase 3 RASolute 302 trial.

August 26
Pancreas
Daraxonrasib doubles survival in advanced pancreatic cancer trial

  • by Doug Brunk

Patients on the oral RAS inhibitor lived a median 13.2 months vs. 6.6 on chemotherapy, with slower progression and longer time to pain and quality-of-life decline.

August 25
Liver
Vietnamese American patients faced highest liver cancer risk, study finds

  • by Doug Brunk

Analysis of more than 4.2 million patients found risk differences that broad racial and ethnic categories obscured — and that narrowed sharply among patients with documented cirrhosis.

August 25
Liver
Liver stiffness readings varied nearly 20% between visits in MASLD study

  • by Henry Thomas

Enhanced liver fibrosis scores varied by 3.4%, but the authors cautioned that the two figures should not be read as a ranking of the tests.